# US 2026/0071260 A1 · Cell-free total nucleic acid controls

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0071260 A1
- Document ID: US20260071260A1
- Status: Published application
- Kind: A1
- Application number: 19/107,217
- Filed: 2023-08-28
- Published: 2026-03-12
- Earliest claimed: 2022-08-29
- Assignees: Microgenics Corporation
- Applicants: Microgenics Corporation
- Inventors: Kunal Banjara; Liang-Chun Liu; Qiang Gan
- Web page: https://patentgrep.com/patent/US20260071260A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6827: for detection of mutation or polymorphism
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2525/121: incorporating both deoxyribonucleotides and ribonucleotides
- C12Q 2537/16: Assays for determining copy number or wherein the copy number is of special importance
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Cell-free total nucleic acid (cfTNA) compositions including genomic DNA, one or more DNA molecules including one or more DNA variants, and one or more RNA molecules including one or more RNA variants are provided. Also provided are kits including the cfTNA compositions. In addition, methods of making and using the cfTNA compositions are provided.

## Claims

### Claim 1

A cell-free total nucleic acid composition comprising:
a) genomic DNA comprising fragments of about 75 to about 600 bp in length;
b) one or more DNA molecules comprising one or more variants selected from the group consisting of one or more single nucleotide polymorphisms (SNP), single nucleotide variants, substitution of one or more nucleic acids (e.g., point mutations), insertions (INS), deletions (DEL), premature stop codons, trinucleotide repeats, translocations, inversions, somatic rearrangements, allelomorphs, splice variants, regulatory variants, gene fusions, and copy number variation (CNV), and any combination of two or more thereof; and
c) one or more RNA molecules comprising one or more variants selected from fusions, isoforms, splice variants, and any combination thereof.

### Claim 2 (depends on 1)

The cell-free total nucleic acid composition of claim 1, wherein the genomic DNA comprises human genomic DNA.

### Claim 3 (depends on 1)

The cell-free total nucleic acid composition of claim 1, wherein the genomic DNA fragments are about 200 bp in length.

### Claim 4 (depends on 1)

The cell-free total nucleic acid composition of claim 1, wherein the concentration of the genomic DNA fragments is about 40 to about 60 ng/μL.

### Claim 5 (depends on 1)

The cell-free total nucleic acid composition of claim 1, wherein:
at least one of the DNA molecules comprises two or more variants;
at least one of the one or more DNA molecules is present in the composition at a variant allelic frequency of about 0.5% to about 1.5%;
at least one of the one or more DNA molecules is present in the composition at a copy number of about 4 to about 7; and/or
the one or more DNA molecules is selected from the group consisting of plasmid DNA, bacterial artificial chromosome DNA, double-stranded DNA fragments, or any combination of two or more thereof.

### Claim at position 6

6-8. (canceled)

### Claim 9 (depends on 5)

The cell-free total nucleic acid composition of claim 5, wherein the double-stranded DNA fragments are gBlock DNA fragments.

### Claim 10 (depends on 1)

The cell-free total nucleic acid composition of claim 1, wherein:
at least one of the one or more RNA molecules comprises in vitro transcribed RNA; and/or
at least one of the RNA molecules is present in the composition at a copy number of about 25 to about 125 copies.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The cell-free total nucleic acid composition of claim 1, wherein at least one of the DNA variants, at least one of the RNA variants, or both comprise a variant associated with a disease or disorder.

### Claim 13 (depends on 12)

The cell-free total nucleic acid composition of claim 12, wherein the disease or disorder is cancer.

### Claim 14 (depends on 1)

The cell-free total nucleic acid composition of claim 1, further comprising an aqueous solution.

### Claim 15 (depends on 14)

The cell-free total nucleic acid composition of claim 14, wherein the aqueous solution is a nucleic acid dilution solution.

### Claim 16 (depends on 1)

A kit comprising the cell-free total nucleic acid composition of claim 1.

### Claim 17 (depends on 16)

The kit of claim 16, further comprising one or more enzymes, buffers, oligonucleotide primers, oligonucleotide adaptors, oligonucleotide probes, or any combination of two or more thereof.

### Claim 18

A method of making a cell-free total nucleic acid composition comprising combining:
a) a population of genomic DNA fragments of about 75 to about 600 bp in length;
b) one or more DNA molecules comprising one or more variants selected from the group consisting of one or more single nucleotide polymorphism (SNP), single nucleotide variants, substitution of one or more nucleic acids (e.g., point mutations), insertion (INS), deletion (DEL), premature stop codon, trinucleotide repeat, translocation, inversion, somatic rearrangement, allelomorph, splice variant, regulatory variant, gene fusion, copy number variation (CNV), and any combination of two or more thereof; and
c) one or more RNA molecules comprising one or more variants selected from fusions, isoforms, and any combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the population of genomic DNA fragments is prepared by:
fragmenting a preparation of total genomic DNA; and
purifying fragments of about 75 to about 600 bp in length.

### Claim 20 (depends on 18)

The method of claim 18, wherein:
the genomic DNA fragments are about 200 bp in length;
the genomic DNA is human genomic DNA; and/or
the one or more DNA molecules comprise one or more of plasmid DNA, bacterial artificial chromosome (BAC) DNA, double-stranded DNA fragments, or any combination of two or more thereof.

### Claim at position 19

21-22. (canceled)

### Claim 23 (depends on 20)

The method of claim 20, further comprising:
fragmenting one or more of the plasmid DNA or BAC DNA; and
purifying fragments of about 100 to about 500 bp in length.

### Claim 24 (depends on 18)

The method of claim 18, further comprising:
preparing the one or more RNA molecules comprising the one or more variants by in vitro transcription from one or more DNA molecules encoding the RNA.

### Claim 25 (depends on 18)

The method of claim 18, further comprising:
measuring the concentration of the genomic DNA fragments, the one or more DNA molecules, and/or the one or more RNA;
determining the copy number of the genomic DNA fragments, the one or more DNA molecules, and/or the one or more RNA; or
both.

### Claim 26 (depends on 18)

The method of claim 18, wherein the combining comprises:
mixing each of the genomic DNA fragments, the one or more DNA molecules, and/or the one or more RNA molecules at a selected concentration or copy number; and/or
combining the genomic DNA fragments, the one or more DNA molecules, and the one or more RNA molecules in an aqueous solution.

### Claim 27

(canceled)
